AU2006274245B2 - Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors - Google Patents

Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors Download PDF

Info

Publication number
AU2006274245B2
AU2006274245B2 AU2006274245A AU2006274245A AU2006274245B2 AU 2006274245 B2 AU2006274245 B2 AU 2006274245B2 AU 2006274245 A AU2006274245 A AU 2006274245A AU 2006274245 A AU2006274245 A AU 2006274245A AU 2006274245 B2 AU2006274245 B2 AU 2006274245B2
Authority
AU
Australia
Prior art keywords
alkyl
alkylene
aryl
heterocyclyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006274245A
Other languages
English (en)
Other versions
AU2006274245A1 (en
Inventor
Joachim Brendel
Armin Hofmeister
Dieter Kadereit
Matthias Loehn
Oliver Plettenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of AU2006274245A1 publication Critical patent/AU2006274245A1/en
Application granted granted Critical
Publication of AU2006274245B2 publication Critical patent/AU2006274245B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
AU2006274245A 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors Active AU2006274245B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05016154 2005-07-26
EP05016154.6 2005-07-26
PCT/EP2006/007139 WO2007012421A1 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2006274245A1 AU2006274245A1 (en) 2007-02-01
AU2006274245B2 true AU2006274245B2 (en) 2011-11-24

Family

ID=34979095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006274245A Active AU2006274245B2 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors

Country Status (31)

Country Link
US (1) US8188117B2 (cg-RX-API-DMAC7.html)
EP (2) EP1910333B1 (cg-RX-API-DMAC7.html)
JP (1) JP5060478B2 (cg-RX-API-DMAC7.html)
KR (1) KR101373535B1 (cg-RX-API-DMAC7.html)
CN (1) CN101228149B (cg-RX-API-DMAC7.html)
AR (1) AR054868A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006274245B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0613861B8 (cg-RX-API-DMAC7.html)
CA (1) CA2615577C (cg-RX-API-DMAC7.html)
CR (1) CR9603A (cg-RX-API-DMAC7.html)
DK (1) DK1910333T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2006000178A (cg-RX-API-DMAC7.html)
EC (1) ECSP088135A (cg-RX-API-DMAC7.html)
ES (1) ES2423006T3 (cg-RX-API-DMAC7.html)
GT (1) GT200600328A (cg-RX-API-DMAC7.html)
IL (1) IL188702A (cg-RX-API-DMAC7.html)
MA (1) MA29636B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008001053A (cg-RX-API-DMAC7.html)
MY (1) MY148479A (cg-RX-API-DMAC7.html)
NI (1) NI200800025A (cg-RX-API-DMAC7.html)
NO (1) NO341888B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ565668A (cg-RX-API-DMAC7.html)
PE (1) PE20070217A1 (cg-RX-API-DMAC7.html)
PT (1) PT1910333E (cg-RX-API-DMAC7.html)
RU (1) RU2414467C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN08039A1 (cg-RX-API-DMAC7.html)
TW (1) TWI383979B (cg-RX-API-DMAC7.html)
UA (1) UA93882C2 (cg-RX-API-DMAC7.html)
UY (1) UY29697A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007012421A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200710951B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51139B (sr) 2005-06-28 2010-10-31 Sanofi-Aventis Derivati izohinolina kao inhibitori rho-kinaze
PT1912949E (pt) 2005-07-26 2011-11-23 Sanofi Sa Derivados de ciclo-hexilamina isoquinolona como inibidores da rho-cinase
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
ATE523493T1 (de) * 2006-09-11 2011-09-15 Organon Nv 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate
JP5421783B2 (ja) 2006-12-27 2014-02-19 サノフイ Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
MX2009005862A (es) 2006-12-27 2009-06-17 Sanofi Aventis Nuevos derivados de isoquinolina e isoquinolinona sustituidos.
WO2008077551A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinolone derivatives
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
DK2102164T3 (da) 2006-12-27 2011-03-21 Sanofi Aventis Cycloalkylaminsubstituerede isochinolin- og isochinolinonderivater
KR20090094338A (ko) 2006-12-27 2009-09-04 사노피-아벤티스 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
WO2008091555A2 (en) * 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CA2710447A1 (en) * 2007-12-26 2009-07-02 Sanofi-Aventis Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
US8541449B2 (en) 2008-06-24 2013-09-24 Sanofi Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors
PL2313374T3 (pl) 2008-06-24 2014-03-31 Sanofi Sa 6-podstawione izochinoliny i izochinolinony
BRPI0914330A2 (pt) 2008-06-24 2019-09-24 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos bl-e policíclicos
US9865233B2 (en) 2008-12-30 2018-01-09 Intel Corporation Hybrid graphics display power management
US8841289B2 (en) * 2009-10-13 2014-09-23 Merck Sharp & Dohme B.V. Heterocyclic derivatives
CN103957711A (zh) * 2011-07-04 2014-07-30 拜耳知识产权有限责任公司 取代的异喹啉酮、异喹啉二酮、异喹啉三酮和二氢异喹啉酮或其各自的盐作为活性剂对抗植物非生物胁迫的用途
HUE027309T2 (en) * 2011-07-08 2016-10-28 Sanofi Sa Crystalline solvates of 6- (Piperidin-4-ylix) -2H-isoquinolin-1-one hydrochloride
CA2837150C (en) 2011-07-08 2019-04-02 Sanofi Substituted phenyl compounds
CA2843777C (en) * 2011-07-08 2018-11-06 Sanofi Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
EP2740458B1 (en) 2012-12-06 2016-08-03 IP Gesellschaft für Management mbH Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
HUE060767T2 (hu) 2013-10-18 2023-04-28 Celgene Quanticel Res Inc Brómdomén inhibitorok
TWI742513B (zh) 2013-11-18 2021-10-11 美商弗瑪治療公司 作為bet溴域抑制劑之四氫喹啉組成物
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP6385584B2 (ja) 2014-12-24 2018-09-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための縮合ピリミジン化合物
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11096909B2 (en) * 2016-04-06 2021-08-24 University Of Oulu Compounds for use in the treatment of cancer
WO2017184462A1 (en) 2016-04-18 2017-10-26 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN106632258B (zh) * 2016-12-15 2019-04-02 三峡大学 四氢异喹啉-2-基芳氧基苯氧基烷基酮化合物及其应用
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11738030B2 (en) 2021-10-30 2023-08-29 Aneuryst, Inc. Treatments for disturbed cerebral homeostasis
WO2024030854A1 (en) * 2022-08-01 2024-02-08 Valo Health, Inc. Process for preparing 6-substituted-1-(2h)-isoquinolinones and intermediate compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403255A1 (en) * 2001-06-12 2004-03-31 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
EP1541559A1 (en) * 2002-07-22 2005-06-15 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
EP0541559A1 (en) 1990-07-31 1993-05-19 E.I. Du Pont De Nemours And Company Catalytic equilibration of selected halocarbons
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
PT863875E (pt) * 1995-09-07 2003-10-31 Hoffmann La Roche Novos compostos 4-(oxialcoxifenil)-3-oxi-piperidina para o tratamento de insuficiencia cardiaca e renal
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
JP2001514259A (ja) 1997-08-29 2001-09-11 ゼネカ・リミテッド アミノメチルオキソオキサゾリジニルベンゼン誘導体
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
KR20020080378A (ko) * 2000-01-20 2002-10-23 에자이 가부시키가이샤 신규 피페리딘 화합물 및 그의 의약
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20040171533A1 (en) 2000-02-29 2004-09-02 Barbara Zehentner Methods and compositions for regulating adiopocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001296008A1 (en) 2000-10-27 2002-05-06 Takeda Chemical Industries Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
WO2004024717A1 (ja) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
WO2004106325A1 (en) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1667979A4 (en) 2003-09-23 2007-04-18 Merck & Co Inc ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS
AU2004276236B2 (en) 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
US20070060595A1 (en) * 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1689719A1 (en) 2003-11-25 2006-08-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
US20080312189A1 (en) 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
PT1912949E (pt) 2005-07-26 2011-11-23 Sanofi Sa Derivados de ciclo-hexilamina isoquinolona como inibidores da rho-cinase
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
DK2102164T3 (da) 2006-12-27 2011-03-21 Sanofi Aventis Cycloalkylaminsubstituerede isochinolin- og isochinolinonderivater
MX2009005862A (es) 2006-12-27 2009-06-17 Sanofi Aventis Nuevos derivados de isoquinolina e isoquinolinona sustituidos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403255A1 (en) * 2001-06-12 2004-03-31 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
EP1541559A1 (en) * 2002-07-22 2005-06-15 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative

Also Published As

Publication number Publication date
MY148479A (en) 2013-04-30
PE20070217A1 (es) 2007-03-19
PT1910333E (pt) 2013-08-01
MA29636B1 (fr) 2008-07-01
DOP2006000178A (es) 2007-02-15
NO20080963L (no) 2008-04-02
RU2414467C2 (ru) 2011-03-20
IL188702A (en) 2012-12-31
CR9603A (es) 2008-03-06
US8188117B2 (en) 2012-05-29
UA93882C2 (ru) 2011-03-25
HK1123035A1 (en) 2009-06-05
EP1910333B1 (en) 2013-05-22
BRPI0613861A2 (pt) 2011-02-15
UY29697A1 (es) 2007-02-28
JP5060478B2 (ja) 2012-10-31
KR20080028971A (ko) 2008-04-02
BRPI0613861B8 (pt) 2021-05-25
NI200800025A (es) 2009-03-03
CA2615577A1 (en) 2007-02-01
TW200918520A (en) 2009-05-01
MX2008001053A (es) 2008-03-19
BRPI0613861B1 (pt) 2019-12-10
CN101228149B (zh) 2013-01-02
NZ565668A (en) 2010-09-30
ZA200710951B (en) 2008-08-27
KR101373535B1 (ko) 2014-03-12
RU2008106950A (ru) 2009-09-10
EP1910333A1 (en) 2008-04-16
NO341888B1 (no) 2018-02-12
WO2007012421A1 (en) 2007-02-01
TNSN08039A1 (en) 2009-07-14
DK1910333T3 (da) 2013-08-19
ES2423006T3 (es) 2013-09-17
CN101228149A (zh) 2008-07-23
JP2009502829A (ja) 2009-01-29
AU2006274245A1 (en) 2007-02-01
AR054868A1 (es) 2007-07-25
CA2615577C (en) 2014-09-09
GT200600328A (es) 2007-02-22
EP2385047B1 (en) 2013-05-29
EP2385047A1 (en) 2011-11-09
TWI383979B (zh) 2013-02-01
US20090093518A1 (en) 2009-04-09
IL188702A0 (en) 2008-08-07
ECSP088135A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
AU2006274245B2 (en) Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
AU2007338406B2 (en) Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase
AU2007338407B2 (en) Cycloalkylamine substituted isoquinolone derivatives
AU2006274246B2 (en) Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors
AU2007338409B2 (en) Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
EP2114920A1 (en) Substituted isoquinoline and isoquinolinone derivatives
AU2006264043A1 (en) Isoquinoline derivatives as inhibitors of Rho-kinase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)